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Abstract 
The experimental work of the final degree project was dedicated to apply the 
knowledge acquired of tissue engineering and regenerative medicine, which are 
branches of biomedical engineering, focusing on the study of rare skin diseases. 
 
The project was developed at CIEMAT (Centro de Investigaciones 
MedioAmbientales y Tecnológicas) organization and with support of biomedical 
laboratories of Universidad Carlos III de Madrid. The project was controlled by Doctor 
Marta García Díez. 
 
The research was focused in the characterization of Dyskeratosis Congenita, 
which present different symtomes, including skin defects, due to lack of dyskerin 
protein. To perform this task In vitro and In vivo experiments are done for the 
characterization of diseased skin. In order to obtain a precise result bioengineered skin, 
histology, antibody detection and other methods are used. 
 
The main objective of this work is the generation and validation of an In vitro 
skin-humanized modelof  DC (Dyskeratosis Congenita) of cells patients, recreating the 
cutaneous phenotype of this disease and then assess therapeutic approaches based on 
genetically modificated DC cells by lentiviral vectors coding for GSE-24.2. 
 
 
 
 
 
 
 
 
14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 
 
Motivation and objectives 
As the importance of skin, not only being the outermost tissue of the human 
body but also taking into accounts its social importance. The study of skin diseases is 
essential for treating millions of people around the world. 
 
With the idea of give a broader view of the characteristics of a diseased skin 
facilitating a diagnostic, some characterization methods are used. The characterization 
of skin gives a wide overview of the structure, function and protein expression in 
Dyskeratosis Congenita skin. 
 
 First, the transfection of a lentivirus containing GSE-24.2 gene to treat 
Dyskeratosis Congenita skin generating and assessing a humanized DC skin model, 
both in vitro and in vivo models. In vitro studies are developed for modeling the disease, 
while in vivo studies are centered in the correction of the disease using the transfection 
of specific protein. 
 
Finally some histological studies are done for the comparison of diseased skin 
with healthy one, also using immunohistochemistry processes; the behavior of the skin 
cells can be evaluated for the development of new therapies to treat skin diseases. 
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Planning 
PHASE 1 (December 2014) SELECTING A RESEARCH TOPIC AND 
LITERATURE SEARCH. Selection of the topic and search of information about it, 
using the knowledge acquired during the university years. 
 
PHASE 2 (December 2014) MENTOR REUNION. Organization and explanation of 
the project, first steps for investigation. 
 
PHASE 3 (First and second week of February 2015) TRANSFECTION OF 
LENTIVIRUS CONTAINING GSE-24.2 GENE. A well-known process is used to 
infect patient cells with the specific protein to treat the disease. Information about the 
transfection is obtained with microscope images. 
 
PHASE 4 (third week of February 2015) RESULTS ANALSIS AND DISCUSSION 
WITH THE TUTOR. After obtaining the results, they were analyzed and discussed 
with the tutor. Following steps for the project are discussed. 
 
PHASE 5 (Fourth week of February and first week of March 2015 ) 
PREPARATION OF BIOENGINEERED SKIN. In order to obtain precise models for 
the characterization of the skin. Cells of patients suffering Dyskeratosis Congenita are 
used. Also healthy cells are used as control. 
 
PHASE 6 (Second and third week of March 2015) IN VITRO AND IN VIVO 
DEVELOPMENT OF BIOENGINEERED SKIN. In vitro experiments using a 
specific culture media for development of skin. In vivo experiments performed using 
mice models for a complex development of skin. 
 
PHASE 7 (First and second weeks of April 2015) HISTOLOGICAL SAMPLES 
PREPARATION AND IMAGE OBTENTION. Samples are prepared using two 
different methods for histology. Staining of samples for the improvement of images. 
Finally a light microscope is used for taking of images 
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PHASE 8 (Third and fourth week of April 2015) IMMUNOCHEMISTRY 
METHODS FOR CHARACTERIZATION OF SKIN. Some antibodies are used to 
detect the concentration of proteins in Dyskeratosis Congenita disease. 
 
PHASE 9 (May, first and second week of June 2015) ELABORATION OF THE 
FINAL MEMORY.  Individual phase for the elaboration of the final document about 
the project. 
 
PHASE 10 (third week of June 2015) FINAL REUNION WITH THE TUTOR. In 
order to improve or change some parts of the document. 
 
PHASE 11 (Third week of June 2015) END OF THE MEMORY. After final 
modifications 
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Introduction 
1. Skin 
 
The skin is the largest organ in the body, comprising 16% of total body weight 
[1] and covering an area of 2m
2
. The principal function of the skin is to form a physical 
barrier against external effects, protecting the body from pathogens and also 
physicochemical changes in the environment. Since is divided in two main layers: 
Epidermis and dermis [2] and a subcutaneous layer called hypodermis. 
 
 
Figure 1. Structure and principal components of skin. The principal components of skin are shown. 
 
The primary function of the epidermis consists on producing a protective, semi-
permeable stratum corneum that permits life. The layers produced in the stratum 
corneum provide a tough and resilient framework for the intercellular lipid lamellae. 
Lysosomal and other enzymes which are present in the extracellular compartment are 
responsible for the lipid remodeling necessary to generate a protective barrier [3, 4]. 
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But, functions of skin are not only protective. Skin plays an important role as 
heat exchanger with the environment. The body maintains its temperature around 37ºC 
regulating the heat released from the skin. If temperature increases inside the body, 
capillary vessels of the skin open and heat escapes through the skin surface. When body 
temperature falls, capillary vessels contract avoiding the expulsion of heat [5]. 
Moreover, skin works as a sensory system receiving stimuli from the environment. It 
senses texture, pressure and temperature. Receptor cells inside the skin carry constant 
information of the central nervous system. 
 
2. Epidermis 
 
Epidermis is a stratified squamous epithelium [6]. The main cells of epidermis 
are keratinocytes which synthesize keratin. Keratinocytes are connected among them by 
desmosomes (i.e.: protein bridges). Epidermis is constantly renewing thanks to the 
stem-cell niche in the basal stratum [7], and then there are constant states of transition 
from deeper layers to superficial ones. The different layers that can be found in 
epidermis are formed by different states of keratin maturation. The four layers of 
epidermis are [6]: 
 
- Stratum basal: It is the innermost layer which lines with dermis, 
attaching to it by hemidesmosomes. As keratinocytes divide and differentiate, 
they move from the stratum basal to the surface of the epidermis. Keratinocytes 
synthesize keratin intermediate filament proteins. These filaments permit the 
cells to connect with those from the stratum spinosum and to the adjacent cells 
by desmosomes [8, 9]. In this layer also are produced the melanocytes, which 
contains a specific pigment called melanin, important to determine the skin color 
[10]. Melanin accumulates in melanosomes that are transferred to adjacent 
keratinocytes where they remain as granules. Melanines also provides protection 
against ultraviolet radiation. 
 
- Stratum spinosum: When cells reproduce and mature, they move 
from stratum basal through outer layers of epidermis. Cells are connected by 
intercellular bridges (desmosomes). In this layer it can be found Langerhans 
cells, which are immunologically active cells derived from the bone marrow. 
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Then this layer plays an important role in immune reactions, with Langerhans 
cells acting as antigen-presenting cells [11]. 
 
- Stratum granulosum: At this level cells undergo apoptosis (i.e.: 
programmed cell death), Nuclei and organelles of the cell are degraded, and cells 
become more flattened. In this layer also lamellar granules are released, which 
are responsible of the secretion of a lipid-rich substance that accumulates in 
intercellular space of the stratum [12]. 
 
- Stratum lucidum: Is a thin and translucent layer composed by 
dead skin keratinocytes. It is found, principally, on the palms of the hands and 
soles of feet [13]. Stratum lucidum is composed by three to five layers of dead 
keratinocytes. The thickness of the layer depends on the mitosis of epidermal 
cells; the darkness is determined by melanosomes. 
 
- Stratum corneum: It is the external layer of epidermis. It is 
composed by hexagonal-shaped, cornified cells known as corneocytes, each 
corneocyte is surrounded by a protein envelope and filled with water-retaining 
keratin proteins. Shape and orientation of proteins will determine the strength of 
the stratum corneum [6]. The structure also facilitates the function of physical 
and water-retaining barrier of the skin [14]. The movement of epidermal cells 
from stratum basal to stratum corneum lasts 28 days and it is called epidermal 
transit time. 
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Figure 2. Structure of epidermis and its different layers. 
 
3. Types of epidermal cells 
 
There are four principal types of cells in epidermis: 
 
- Keratinocytes: They are the most abundant cells in epidermis 
(95% of cells). These cells are responsible of the tight-junction formation with 
the nerves of skin. Moreover, Keratinocytes facilitates the maintenance of 
Langerhans cells of the epidermis and lymphocytes of dermis in place [15]. 
In addition to their structural role, keratinoytes take part on immune system 
protection. They prevent toxins and pathogens from entering in the body and the 
loss of heat, moisture and other important components. In addition, their 
principal immune role is immunomodulation, responsible for secreting 
inhibitory cytokines in absence of injury, but when an injury occur, they 
stimulate inflammation and activation of langerhans cells. 
 
- Langerhans cells: They are members of dendritic cell family and 
reside near the epidermal basal layer. Their primary function reside in antigen 
presentation for immune cells, LC acquire antigens in peripheral tissues and 
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transport then to lymph nodes faciliting the immune response by the organism. 
Moreover, LC Works as mediator of tolerance [16]. 
 
- Melanocytes: They are cells of neural crest origin. In epidermis, 
they form relations with keratinocytes using their dendrites. But, their principal 
function consist on skin pigmentation by the release and distribution of melanine 
through though the skin. Melanocytes are regulated by melanocortin peptide 
alpha-MSH (Melanocyte-Stimulating hormone) [17]. 
 
 
- Merkel cells:  They are the fewest numerous cells in epidermis. 
MC is found isolated in the epidermis or associated with epithelial nerve 
endings. These types of cells are supposed to derive from the neural crest as 
Melanocytes, which allow living in union with epidermal and neural cells. 
Principal function of MC consists on a specific, slowly adapting sensory touch 
receptor [18]. 
 
4. The dermal-epidermal junction 
 
The relation and anchoring between dermis and epidermis is an indispensable 
structure for skin interactions with other tissues and for protection of environment, it is 
called dermal-epidermal junction. Its principal functions are: bind tightly dermis and 
epidermis, determine the polarity of basal keratinocytes of epidermis, works as a 
selective barrier to protect the organism and plays an important role in wound healing 
[19]. 
 
Centering in the structure of DEJ, it can be differentiated in four parts: First, 
hemidesmosomes of basal keratinocytes in their cell membranes; second, the lamina 
lucida that anchor filaments transverse and can be seen by electron microscopy; third 
the lamina densa composed principally by collagen IV and laminin family proteins; and 
fourth, the sub-basal lamina containing anchoring fibrils [20]. All the parts of DEJ 
contains ubiquitous basement membrane components, including laminin, collagen type 
IV, proteoglycans (predominantly in lamina densa) and collagen VII forming anchoring 
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filaments in the sub-basal lamina densa. 
 
 
Figure 3. Conformation of dermal-epidermal junction. DEJ is formed by two layers: lamina lucida and lamina  
densa. The principal components of DEJ are: Laminin 5/6, Collagen XVII/XXIII, α3β1 integrin, etc. 
 
5. Telomerase  
 
Telomerase (or telomere terminal transferase) is a ribonucleoprotein that adds 
DNA sequence repeats (specifically “TTAGGG”) to the 3’ end of DNA strands in 
telomere regions [21]. In linear DNA, there is no place to produce the RNA primer 
needed to start the final Okazaki fragment on the lagging strand when the replication 
fork reaches the end of the helix. If telomerase is not present, a single stranded region of 
DNA would be produced (100 to 200 nucleotides) and DNA polymerase cannot produce 
a daughter strand. This would produce the shortening of chromosomes each replication 
cycle. Telomerase is a reverse transcriptase that carries its own RNA molecule, which is 
used as a template when elongates telomeres.  
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Figure 4. Group of molecules which form human telomerase. The most important parts are: TERT (telomerase 
reverse transcriptase), TERC or hTR (Telormerase RNA) and dyskerin. 
 
 
Human telomerase is formed by different molecules: telomerase reverse 
transcriptase (TERT), telomerase RNA (TERC) and dyskerin (DKC1) [22]. The genes 
of telomerase molecules are located on different chromosomes in human genome. 
 
TERT is capable to add the six nucleotide repeating sequence (TTAGGG), using 
TERC, to the 3’ strand of the chromosomes. The TTAGGG repeat forms the telomeres. 
Then, telomerase can add the 6 nucleotides repeat sequence; realign the new 3’ end of 
telomere to the template, and repeat the process to avoid telomere shortening [23]. 
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Figure 5.Scheme of telomerase function. (A) Normal replication process, there is a gap in 3’ in the lagging strand. 
(B) Function of telomerase, reducing the gap of 3’. (C) In blue, chromosomes; in yellow, telomerase. 
 
 
Telomerase is a protein important for clinical studies. It plays a critical role in 
cell aging and cancer development. Moreover, the lack of telomerase produces several 
rare diseases as Dyskeratosis Congenita.  
 
6. Dyskeratosis congenita 
 
Dyskeratosis Congenita is an heterogeneous disease which present different 
symptoms: skin alterations, as nail dystrophy, hyperpigmentation and oral leukoplakia 
(Fig. 1); pulmonar fibrosis and bone marrow deficiencies [24, 25]. 
 
 
 
 
 
 
 
 
 
Figure 6. Dyskeratosis congénita symptoms in skin. A) skin hiperpigmentation. B) Nail dystrophy. C) Oral 
leukoplakia.  
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DC is caused by deficiencies in telomerase ribonucleoproteic complex, which 
function is to maintain the length of telomeres in the chromosomes. DC can be cause by 
mutations that affect to any gene codifying one of the components of Telomerase 
complex. Depending on the affected component the symptoms, severity and inheritance 
of the disease change [24, 26]. 
 
 Recessive Dyskeratosis Congenita linked to X chromosome is caused by 
mutations in gene DKC1, which codifies for Dyskerina [27]. The most usual mutation 
that affects this gene is a non-sense mutation that introduces a premature stop codon. 
The Dyskerina is a protein of telomerase complex which function is matures the 
telomeric RNA to make its task. In this way, when the mutations affect the DKC1, the 
telomeric RNA is reduced and the activity of telomerase is reduced and telomeres are 
shortening [24, 26, 27]. These alterations in the telomere length maintenance drive to 
aging and cell senescence. The lack in telomerase activity affects to regenerative cells in 
tissues which are in constant renewal, as in the case of hematopoietic cells and basal 
epidermal cells. Then, the deficiency in telomerase activity of keratinocytes entails 
telomere shorten, altering cellular proliferation and perturb the capacity of epidermal 
renovation [26]. 
 
7. Gene therapy 
 
Gene therapy is a therapeutic strategy based on the genetical modification of 
somatic cells through the addition of nucleic acids with the final proposition of cure 
inherited and acquired diseases [28]. 
 
Gene therapy can be developed using two different strategies: 
 
- In vivo strategy is based in local or systemic administration of the 
vector in the organism. In this way, the vector inserts the transgene in target 
tissue to create a specific functional gene. 
 
- Ex vivo strategies begin with the extraction of patient cells of the 
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target tissue. Cells are disaggregated and cultured In vitro, then they are 
genetically modified with the transfection vector. Genetically modified cells are 
selected depending on their capacity to express the exogenous gene. These cells 
are amplified and recollected to reintroduce in the patient. Gene therapy 
efficiency is highly superior when cells are treated ex vivo, then this strategy is 
used mostly [29]. 
 
 
Figure 7. Normal procedure for ex vivo gene therapies. Cells are harvested from patient. Trangene vector is 
developed in laboratory and transfected to the cells. Finally infected cells are reintroduced in the patient. 
 
Depending on the durability of the trasgene therapeutic effect, gene therapy can 
be transitory or permanent: 
 
- Transient gene therapy: Its main objective is to maximize a 
transitory physiological process, for example wound healing. 
 
- Stable gene therapy: Its function consists on a permanent 
correction of a disease. With this objective, the therapy needs to apply two 
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principal requisites: First, target cells for transgene vector must be stem cells. 
Secondly, Vector need to be able to integrate the transgene in the genome of 
stem cell, in such a way, the trangene is transferred to its progeny [30]. 
 
Finally, depending on the strategy used for genetic correction in cells two 
different therapies are used: 
 
- Addition gene therapy: One, or more, copies of the transgene are 
introduced in the cell and added to the genome in an integrative or non-
integrative form. 
 
- Substitution gene therapy: At least a mutated allele of gene is 
eliminated of the genome; it is replaced by a copy of the transgene using 
homologous recombination [31]. 
 
8. Vectors for gene therapy 
 
Gene therapy systems need to be safe, effective and capable to work in target 
cell type. Moreover, they need to guarantee the stable expression of transgene. Vectors, 
which are DNA carrier molecules, are the regular method for transgene transfection. 
Vectors are systems that facilitate the transference of exogenous gene to target cells. 
Vectors can be classified in viral and non-viral vectors. 
 
 Cells can be genetically modified using different kind of vectors, depending on 
the selectivity, efficiency and transfer of the trasgene to cells. Non-viral vectors have 
some limitations in the transfer of the trasgene to cells, due to their low transfection 
efficiency [32, 33]. In the case of transfection to epidermal cells, lentiviral vectors are 
widely used. 
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Figure 8. List of the different types of vectors (viral and non-viral) for gene therapy. Lentiviral and retroviral 
vectors are the most used because they insert in the genome. Adenoviral vectors offer more space for transgene, but 
they are eliminated by immune system. Adeno-associated viral vectors reduce the immune response with respect to 
adenoviral vectors. Finally the most usual non-viral vector is a liposome + plasmid complex. It offers, unlimited sized 
genome and no immune response, but its efficiency is low. 
 
9. Lentiviral vectors 
 
Lentivirus is a subclass of retrovirus. Lentiviral vectors are capable to integrate 
into the genome of non-dividing cells (while other retrovirus only can infect dividing 
cells). The viral genome in the form of RNA is reverse-transcribed when the vector is 
inside the cell to produce DNA. This DNA is inserted at a random position in the 
genome by viral integrase enzyme. The vector remains in the genome and is passed on 
to the progeny when cell divides [33].  
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Figure 9. Resume of the lentiviral infection method. The lentiviral vector enters in the cell and converts the viral 
RNA in viral DNA by the reverse transcriptase. Viral DNA is inserted in cell genome. Transgene carrying the wanted 
protein is expressed.  
 
The site of integration is unpredictable and can produce some problems. It can 
disturb the function of cellular genes and lead to the activation of oncogenes promoting 
the development of tumors. However, some studies have shown that lentiviral vectors 
have lower tendency to integrate in potential cause cancer than other viral vectors [34]. 
 
Lentiviral vectors never carry genes required for their replication for safety 
reasons. To produce a lentivirus several plasmids are transfected to packaging cell line 
(normally 293T cells are used). The plasmids used include: virion protein encoding 
plasmid, as the capsid and the reverse transcriptase; and the specific gene to be 
delivered by the vector in genome. 
 
Lentivirus contains six accessory genes: nef, vif, vpr and vpu, related with 
virulence proteins; tat, which codifies a regulatory protein proviral DNA transcription; 
and rev, which codifies a protein that binds to responsive element RRE (Rev responsive 
element) situated in the transcription process of env gene for the exportation of viral 
mRNA from nucleus to cytoplasm.  
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The most common virus used as lentiviral vector is HIV-1 (human 
immunodefficient virus 1). The own codifying genes of lentivirus are substituted by a 
plasmid inserting a transgene, necessary genes for vector packaging are introduce in 
trans. 
 
Cellular toxicity caused by several lentiviral proteins, necessary for vector 
packaging, reduces the possibility of using stable packaging methods. Then, lentiviral 
vectors are produced in transitory packagning systems. This lentiviral vector is obtained 
with the transfection of four plasmids: one for the transgene and 3 helper plasmids: for 
genes gag/pol; for gene rev; and another for the gene codifying the envelope. 
 
 
Figure 10. Scheme of lentiviral genome of HIV-1. The lentivirus contains: nef, vif, vpr and vpu related with 
virulence proteins; tat, related with proviral DNA transcription; and env for exportation of viral mRNA from nucleus 
to cytoplasm. 
 
 
Figure 11. Scheme of the necessary plasmids for packaging of lentiviral vectors. The lentiviral vector is 
composed by: envelope plasmid, packaging plasmids (pro/pol and REV genes) and the transference vector carrying 
the transgene. 
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10. Development of bioengineered skin in animal 
models and vector transfection 
 
During the last years the field of genetic modification has evolved for fibroblast 
and keratinocytes, and also for epidermal bioengineered tissues. Skin is a suitable organ 
for gene therapies: it is accessible, can be modified in vivo and in vitro and is easy to 
remove in case of adverse symptoms. The characteristics of keratinocytes allow 
extracting and isolating from the patient, maintain in a cell culture and be infected ex 
vivo. After infection cells are selected, isolated and expanded in a culture to be 
introduced again in the patient [35]. Keratinocytes infected in vitro maintain their 
proliferative, maturation and differentiation activities [36]. Nowadays, the strategies for 
transfection in vitro are well-known, in order to introduce a trasgene, with the necessary 
genetic information to target molecules.  
 
Due to virus in eukariotic cells and, in particular those that affect to humans, 
have evolved to transfer their genetic material with high efficiency in human cells, the 
vectors derived from them transduce much more efficiently than non-viral vectors.  
Retrovirus and lentivirus are very efficient, when it is required a more stable expression 
of the trasgene. But, when it is wanted a transitory expression, non-integrative vectors, 
as Adenovirus, are more appropriate [37]. 
 
Nowadays, it is possible to infect primary keratinocyte cultures with viral 
vectors, as retrovirus [38,39] and lentivirus [40]. Lentiviral vectors are capable to infect 
in vitro keratinocyte cultures with higher efficiency and also promote the stability of 
trasgene expression, thanks to a specific characteristics: they are integrated, do not 
possess genetic regulatory U3 region, they integrate in target cell genome using LTR 
regions through homologous recombination [40]. The integration capacity promotes the 
infection efficacy and, once integrated, infected cells over express the transcripts respect 
to other vectors. 
  
Moreover, it has to be taken into account that systems for gene transfer, used to 
correct genetic abnormalities, must be safe. Then it is necessary to demonstrate the 
security of gene transfer in infected cells. Lentiviral vectors have less probability to 
suffer inserccional tumorgenesis [41]: vectors are integrated by LTR regions and its 
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genetic expression is regulated by cell promoter, reducing the probability to activate the 
expression of near genes and produce oncogenesis in cells. 
 
In the other hand, epidermal bioengineering is capable to develop in vitro 
bioengineered skin. The development of differentiated skin is possible thanks to 
regenerative capacity of epidermal stem cells. Keratinocytes, which constitute the 
epidermal component of bioengineered tissue, are cultured over a matrix of fibrin, 
fibroblast and specific growth factors [42]. Fibrin matrix acts as a scaffold and 
stimulates the proliferation of keratinocyte. This tissue mimics the natural process of 
wound healing allowing to recreate in vitro the physiological and functional 
characteristics of natural skin [43]. Moreover, it has been established a humanized 
mouse model, based on a graft of skin equivalent in a immunodefficient mouse. Then, it 
is possible to obtain a stratified and differentiated human skin which reproduces the 
natural characteristics in human epidermis [44]. 
 
 
Figure 12. Scheme of the humanized skin animal models. First, bioengineered skin is composed using cells of the 
patient (keratinocytes and fibroblast) and a fibrin matrix. The bioengineered skin is grafted on immunodefficient 
mouse for maturation in vivo. 
 
This model is not only important for study of physiological dermal processes, 
but also to generate preclinical models for dermal diseases [44]. The use of diseased 
keratinocytes as epidermal component of the equivalent skin and the posterior graft in to 
the immunodefficient mouse allow generating a human epidermis in a mouse that 
reproduces the pathologic phenotype of the disease [45]. 
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This strategy facilitates the study and preclinical model generation for some skin 
diseases [45]. This model has been also used for genetic correction of keratinocytes in 
vivo.  
 
Then, the development of skin equivalents, the generation of preclinical animal 
models and the evolution of gene therapies gives the possibility to characterize the 
Dyskeratosis Congenita disease. Using a lentiviral vector that includes Dyskerin (GSE-
24.2), as approximation of gene therapy of DC, and developing in vitro skin equivalents 
with transfected keratinocytes to generate a humanized mouse model for Dyskeratosis 
congenita. 
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Materials and methods 
1. Transfection of GSE-24.2 gene 
 
Cell culture. Primary fibroblast and keratinocytes from Dyskeratosis Congenita 
skin and healthy patients were obtained through skin biopsies of the patients. DC cells 
were obtained from Dra. Perona. 
293T (human embryonic kidney cells) cells are cultured using DMEN 
(Dulbecco’s modified  eagle medium) with inactivated serum 10% medium in p100 
dishes. Cells were counted to have 3 millions of 293T per dish. Incubate at 37ºC during 
24 hours. 
Lentivirus production. The preparation of lentiviral vector is composed by 
different parts:  
- Lentiviral plasmid GSE-24.2 gene + GFP, 6.04µL at 1, 49µL/µG (only in DC 
dish) 
- Plasmid-GFP (only GFP), 11, 25µL at 0, 5µg/µL (only in control) 
Helper plasmids: 
- Genes gag/pol: 2, 42µL at 2, 07µg/µL 
- Gene rev: 1, 73µL at 1, 3µg/µL 
- Gene codifying the envelope: 1, 75µL at 1, 8µg/µL 
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When four plasmids are mixed, 61µL of 2, 5 M CaCl2 2M are added. Then, 
1.250 μl of 2X HBS (HEPES 100 mM (GibcoBRL); NaCl 281 mM; Na2HPO4 1,5 mM; 
are added to the mixture and bubble to homogenize. 
Transfection of the vector. First, 293T medium is changed by 9mL of DMEN + 
3µL of Cloroquine (specific medium for CaCl2). Lentiviral sample is added to the 
mixture drop by drop. Incubate the culture at 37ºC during 6 hours. The medium is 
changed again by fresh DMEM and incubated at 37ºC 
After 24 hours cells are observed at the microscope, using fluorescent light to 
detect GFP concentration. Medium is changed to kcinact and incubated at 37ºC during 
24 hours. 
The final step consists on the use of supernatant of transfected cells to add it to 
keratinocytes. The medium of transfected cells is retired and fresh kcinat medium is 
added, cells are incubated at 37ºC during 24 hours. Medium of transfected cells is 
filtered at 0.22. Then the medium is added to DC keratinocytes during 6 hours at 37ºC 
and changed by fresh medium 24 hours. The process is repeated twice for a higher 
transfection. 
Finally, 293T cells are no more useful. DC Keratinocytes are followed daily 
changing the medium every 48 hours. 
Figure 13. Representation of the structure and compostion of lentiviral vector. First represents the 
control with GFP. The second also contains the GSE-24.2 protein (DC+IRES). Both vectors are formed 
by LTR sequences. The regulatory región U3 has been eliminated. Genetic expression is regulated by the 
promoter of phosphoglycerate kinase and contains a post-transcriptional regulatory sequence, wPRE. GSE-
24.2 vector codifies for dyskerin and GFP, it has also incorporated IRES sequence, which facilitates GFP 
traduction. 
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2. Bioengineered skin fabrication 
 
The bioengineered skin is based in a fibrin matrix approach. Fibrinogen, 
obtained from cryoprecipitate plasma of pig blood, is used as a source for the matrix. 
Once the plasma is extracted it is treated with three freeze-thaw cycles to obtain the 
cryoprecipitate, which is centrifuged at 3500 rpm during 15 minutes, 4ºC. 
 
Supernadant is discarded and the pellet is resuspended in NaCl 0, 9% and 
incubated at 37ºC to dissolve completely the fibrinogen [46]. The production of fibrin 
gel consist on: mixture 1,5mL of fibrinogen (cryoprecipitate) with 5mL of DMEM 
supplemented with 10% FBS and 2,5x10e5 human fibroblast, 250 UI of bovine 
aprotinine are also added. Immediately after, 0,5mL of CaCl2 0,025 mM and 5, 5 UI of 
bovine thrombin to a final volume of 3mL. 
 
The mixture was initially deposited in a inserts of 6-well transwell plates (3 with 
DC patient fibroblast and 3 controls), where it solidifies at 37ºC during 2 hours. Part of 
the mixture is deposited in 6 well-plates for animal model study (2 for orthotopic 
method for murine skin transplantation, 2 for Barrandon method). Finally, Keratinocytes 
are added to the gel. The gel is again incubated at 37ºC, O/N.  
 
3. Growth in vitro and in vivo 
 
The growth and differentiation of skin is performed with two different 
approaches: in vitro and in vivo in an immunodefficient mouse model. 
 
In vitro experiment was performed using 6-well transwell plates; DMEN 
medium is used and changed every 4 days for the growth of the tissue. 
 
When keratinocytes reach confluence, engineered skin equivalents were allowed 
to differentiate at the air-liquid interface for 17 days at 37ºC in a CO2 incubator. The 
medium in changed every two days (Figure 14). 
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Figure 14: Skin Equivalent structure. (a) Schematic of a skin equivalent in a cell culture insert with a PET 
membrane (1 μm pores). The surface keratinocytes are exposed to the air, while the construct is fed by medium from 
below. (b) Skin equivalent after incubation for 17 days at the air/liquid interface showing an intact and dry surface, 
ready for studies. 
 
In vivo experiment was performed using immunodeficient mice as an animal 
model. Two approaches were used:  
 
First, orthotopic method for murine skin transplantation. An incision is done in 
the back of the mouse.  The skin is extracted and the bioengineeed skin is set in position 
(keratinocyte layer is set above). Murine skin pass through a freeze-thaw step 3 times to 
kill it. The skin is again put in place to fix the bioengineered skin gel and is stitched for 
a correct fixing. The result of skin growth can be seen in 2 months. (Figure 12) 
 
On the other hand, the second approach is Barrandon method. It consists on 
doing an incision in murine skin. A sheet of silicone is inserted and bioengineered skin 
is introduced with keratinocyte layer lying with the silicon sheet. The incision is closed. 
The results can be seen in 15 days, but it does not recapitulate the morphology of skin 
as orthotopic skin graft does (Figures 15 & 16). 
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Figure 15. Principal steps for bioengineered skin graft in a murine model. A) Extract the mouse skin at the back. 
B) & C) Devitalization of skin by 3 thawn freezing cycles. D) Preparation of bioengineered skin. E) & F) Transplant 
of bioengineered skin in the mouse. G) & H) Suture the desvitalized skin over the bioengineered equivalent. I) & J) 
Regeneration of human skin in mouse.  
 
 
Figure 16. Graphic representation of the technique described by Barrandon et al. for dorsal graft implantation 
in athymic mice. 
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4. Histology & immunohistochemistry 
 
Bioengineered skin growth in vitro and in vivo are prepared for histology and 
future immunohistochemistry studies. Two approaches are used for histology 
preparation: paraffin and frozen sectioning. 
 
Paraffin proccesing of tissue and sectioning. First of all, tissue fixation using 
formalin and ethanol as principal agents is used. When the tissue is fixated paraffin 
infiltration is produced. In this procedure, tissue is dehydrated through a series of 
graded ethanol baths to displace the water, and then infiltrated with paraffin wax. 
Tissues processed into paraffin will have wax in the cassettes; in order to create wax 
blocks, the wax is melted away placing the entire cassette in 58ºC paraffin bath for 15 
minutes. 
 
Once the sample is embedded in paraffin wax, it is freeze to make the paraffin 
wax easily cut. A microtome is used for sectioning the sample. The size of the slices is 
fixed in 3µm. The slices are rapidly set in water at 40ºC, and taken by glass slides for 
posterior staining. 
 
Frozen sectioning. The tissue is embedded in a gel like medium called OCT 
(optimal cutting temperature compound), which contains ethilene glycol and polyvinil 
alcohol. The temperature is reduced to -12ºC (specifically for skin). When the OCT with 
tissue inside hardens, the cryostat is used. The size of slicing sections is 5µm and they 
are directly set in glass slides for a future treatment. The quality of the slides produced 
by frozen section is lower than paraffin embedded tissue processing, but it is less time 
requiring. 
 
Hematoxilin & Eosin staining. Paraffin samples are processed using the 
following proccedure for staining tissues: 
1. Deparaffinize and hydrate to water 
2. Introduce in hematoxylin for 15 minutes 
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3. Wash in running tap water for 20 minutes 
4. Counterstain with eosin for 2 minutes. 
5. Dehydrate in 95% and 100% alcohol, two changes of 2 minutes 
each or until excess eosin is removed. Check under microscope 
6. Clear in xylene, two changes of 2 minutes each 
7. Mount and analyze with microscope. 
 
Antibody detection. Deparaffinize Samples are washed in PBS and it is blocked 
in PBS + BSA (bovine serum albumin) 3% for 15 minutes. Antibodies are added, in this 
study we use five different antibodies: Involucrin (1:100 in PBS with 3% BSA, mouse 
antibody), GFP (1:200 in PBS with 3% BSA, rabbit antibody), k14 (1:100 in PBS with 
3% BSA, rabbit antibody), ki67 (ready to use) and Vimentin (1:100 in PBS with 3% 
BSA, mouse antibody). Samples are stored 20 minutes at 37ºC. Again wash of PBS and 
the second antibody is added: Anti-rabbit (1:25 in PBS) for GFP, ki67 and k14; and 
Anti-mouse (1:250 in PBS) for vimentin and involucrin. Again, samples are stored 20 
minutes at 37ºC. Finally, another fluorescent staining called DAPI is used to label the 
nuclei of cells. Ready for taking images under fluorescent light microscope. 
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Results & Discussion 
In this section all the results obtained will be evaluated. The first part consists on 
the efficacy of the transfection lentiviral vector. Secondly, the generation of In vitro and 
In vivo models for the comparison between DC skin and control morphology with 
hematoxylin and eosin staining. Finally, immunohistochemistry results for the different 
protein expression in DC skin and control. 
1. Transfection of lentiviral vector 
 
The objective of this study consist on quantify the efficacy of infection with 
lentiviral vectors, by the level of expression of GFP in infected keratinocytes. As it is 
said before, two cultures of 293T cells were developed. One with the vector carrying the 
GSE-24.2 + GFP genes and another one only with GFP to serve as a control. The 
supernatant of 293T cells containing the viral vectors are used to infect the 
keratinocytes that will form the bioengineered skin. It is important to remark that 
keratinocytes infected with GSE-24.2 and control (only GFP) are from Dyskeratosis 
Congenita patients. 
 
Using a blue-light microscope, the results of the vector transfection can be 
evaluated. First, images without fluorescence are taken to see the development of 
keratinocyte cell culture. (Figure 17 & 18) 
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Figure 17. DC keratinocytes transfected with GSE24.2 + GFP vector.   
 
Figure 18. DC keratinocytes infected with GFP vector. 
 
In both images, it can be seen the two keratinocyte cultures. The first one 
represents the culture infected with GSE-24.2 lentiviral vector and the second represents 
the control (DC keratinocytes + GFP). The two cultures show normal growth of cells.  
 
Using blue-light microscope, the expression of GFP can be easily quantified. 
First for the GSE-24.2 culture the following images are obtained. (Figure 19) 
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Figure 19. DC keratinocytes transfected with GSE-24.2 + GFP (Left) and expression of GSE-24.2 + GFP by 
DC keratinocytes (right). DC keratinocyte culture is shown normal growth of cells in culture (left). But, using blue-
light microscope, no fluorescence can be seen in the image (right). This means that there is no presence of GSE-24.2 
+ GFP vector. So, the transfection has not worked as supposed. 
 
The left image is taken using bright field light. The right one only uses 
fluorescent light to see GFP. As can be seen in right image, no GFP is present. This can 
be caused by several reasons: incorrect infection, problems with GFP sample, problems 
with the miscroscope, etc. 
 
As no presence of GFP in the first culture, the study of the control culture is 
necessary to evaluate the possible problems. The following image shows the 
representative case (Figure 20): 
 
 
Figure 20. DC keratinocyte transfected with GFP vector (left) and expression of GFP in DC 
keratinocytes (right). DC keratinocytes culture shows normal growth of cells (left). Using blue-light 
microscope some green fluorescence is represented, which means that GFP is expressing in the culture. So, 
the transfection has worked as supposed. 
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In this case, it can be easily seen the GFP presence. The GFP has been dispersed 
by all the culture as we were trying to achieve. 
 
So, we can conclude that the lack of presence of GFP in the GSE-24.2 culture 
must be related with the plasmid containing the therapeutic gene plus the GFP or with 
errors in the protocol process in that culture, because the control culture (DC 
keratinocytes + GFP) shows a correct infection by the cells. 
 
The experiment was repeated again, in order to infect diseased cells. Even so, 
the result obtained was the same. Then the final conclusion about the lack of expression 
of GFP in the DC keratinocyte culture can be produced by: the bad quality of the sample 
containing the protein plus the GFP or incorrect infection with the viral vector to the 
cells. Due to the infection problems with the virus containing the therapeutic gene, the 
work will focus on the development of a model for DC. 
 
2. In vitro model of DC: Phenotypic and biochemical 
characteristics 
 
Hematoxyilin and eosin staining is the standard method for histological tissue 
stain to study the architecture and phenotypic characteristics of the samples. 
Hematoxyilin color the nuclei of cells with a dark blue color. Eosin stains the rest of the 
tissue with different shades of pink, red and orange. 
 
The staining of tissue samples is very important for the characterization of the 
tissue. The obtained results will be useful for knowledge about the differences between 
Dyskeratosis congenital skin and normal one. 
 
For this experiment, 6 different samples are used: 3 in vitro bioengineered skin 
controls, 3 in vitro bioengineered DC skin. In Figure 21, it is shown one representative 
experiment. 
 
Images are taken at 10x, to study deeply the characteristics of different tissues. 
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Figure 21. In vitro bioengineered skin from: Healthy cells (left) and DC cells (right). The differences between 
healthy and DC skin are easily appreciable. Healthy skin shows homogeneous structure in all layers of skin, while 
DC skin shows a hyperplasic behavior of the epidermal layer. The distribution of stratum corneum in DC skin is also 
heterogeneous, and it can be explained by the hyperplasia of epidermis. Finally, dermal layer also present some 
differences, as the dermal-epidermal junction and the loose conformation of fibroblast in DC skin 
 
The control sample is in vitro bioengineered skin with healthy keratinocytes and 
fibroblast. In vitro model can be useful for a comparison with diseased skin, in order to 
determine the principal differences in the global characteristics of dermis and epidermis 
between DC and healthy skin. 
 
The principal characteristics of skin control showed above are: homogeneous 
thickness of epidermal layer; correct formation of the stratum corneum in the outermost 
part of epidermis; correct attachment between layers in the epidermal-dermal junction 
and a relatively well-formed matrix among fibroblast in the dermis. 
 
The differences in the development of skin between DC and healthy are easily 
visible. In diseased skin, Stratum corneum is hyperkeratotic (a thickening of the outer 
layer of the skin and more compact) compared with the “normal basket-weave 
structure” in normal skin. 
 
Moreover, the entire epidermal layer presents a hyperplasia. This condition 
increases the number of normal cells in a normal arrangement in an organ or tissue, 
which increase the volume, compared with skin generated by healthy keratinocytes. 
Then, the structure of epidermis in in vitro DC skin doesn’t allow the correct 
functionalization of epidermal layer. 
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The attachment between layers in DC skin is practically null along the entire 
dermal-epidermal junction. As in the case of heterogeneous epidermal layer, the reduced 
dermal-epidermal junction reduces the function of skin as a whole. This facilitates the 
detachment of epidermis producing problems for normal development of skin. To 
confirm this conclusion more studies with different attachment markers must be done. 
For example markers for Collagen VII/XVII, integrins, laminins, etc. 
 
Finally, the dermis formed by fibroblast presents a loose conformation in 
comparison with healthy skin. The loose structure of this layer has influence in the 
whole function of skin reducing the mechanical properties of it. 
 
Two principal conclusions can be obtained from the comparison between both 
kinds of skin: First, DC bioengineered skin shows hyperkeratosis and hyperplasic 
characteristics, due to the incorrect function of diseased cells. Instead of we are 
obtaining an overall view about the structure of skin, it is easily seen the problems that 
present the diseased skin. 
Secondly, that once we have an overall vision about the in vitro skin, it is 
necessary a precise study to a better understanding of the difference between healthy 
and diseased skin. Then, with this purpose, immunohistochemistry processes are used to 
see the difference in protein expression between normal and DC skin. 
 
3. Immunohistochemistry 
 
Immunohistochemistry refers to the process of detecting antigens (i.e.: proteins) 
in cells of a tissue section by using antibodies that specifically binds to antigens in 
biological tissues. As we are treating to modeling a skin disease, the antibodies used are 
those that have significance in skin development, epidermal differentiation and growth, 
dermal structure, etc.  
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GFP 
GFP is used as a reporter gene of expression. In this case, GFP was used as a 
control in transfection to determine if keratinocytes were infected by the lentiviral 
vector. 
In Figure 22, the expression of GFP is shown: 
 
Figure 22. GFP expression in control (left) and DC (right) keratinocytes. The image shows the transfection of the 
GFP vector in both, control and DC sample. DAPI is used to stain cell nucleus in blue. 
 
Images obtained under fluorescent microscope demonstrate that keratinocytes 
(control and DC) were infected correctly and express GFP proteins properly. The idea is 
to achieve the same result but with the GSE-24.2 lentiviral vector.  
Involucrin 
Involucrin is a protein that works as a structural component in mature squamous 
epithelial cells. Then, it is a marker used for terminal differentiation in epidermal layer 
(Figure 23). 
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Figure 23. Expression of involucrin in control (left, green) and DC (right, red) in epidermal layer. Involucrin is 
used as a marker for terminal differentiation. Then, the expected result is to find it at the outermost part of epidermal 
layer. The control sample shows involucrin expression in the expected place (left, green). But in DC skin, it can be 
seen expression of involucrin in internal parts of epidermis (right, red). This means abnormal maturation and 
differentiation of keratinocytes in DC skin. 
 
The green fluorescence represents the involucrin in control sample in the 
outermost part of epidermal layer, which means that cells are correctly differentiating 
and maturating from stratum basal to stratum corneum through the epidermis. 
 
For DC skin, two important conclusions can be obtained: First, the expression of 
involucrin in the outermost part of epidermal layer is reduced with respect to healthy 
skin. Second, In this case the presence of involucrin is not reduced to the external part 
of epidermis, it is also found inside the epidermal layer. This means an abnormal 
maturation and differentiation of keratinocytes in DC skin. It is also related with the 
migration of cells through the epidermal layer. 
Ki67 
Ki67 is a protein strictly associated with cell proliferation. The protein is present 
during all active phases of the cell cycle (G1, S, G2 and mitosis), but absent in resting 
cells (G0). This characteristics makes ki67 a good marker about the growth fraction of a 
given cell population. 
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The results obtained from control and DC skin are: 
 
Figure 22. Expression of ki67 in control (left) and DC (right) skin. Ki67 is used as a marker of cell proliferation. 
The comparison between ki67 in control and DC skin shows that it is higher in DC skin. But, it is supposed that DC 
cells show less proliferation level due to lack of telomerase. Then, the result is unclear. 
 
Instead of the expression of ki67 is low, it is present in cells. This means that 
cells are proliferating and generating new cells for epidermal layer. The proliferation of 
epidermis is very important for maintain homeostasis of the tissue. 
The comparison in the level of proliferation (Ki67 positive cells) is higher in the 
DC skin than in the control one. This is in agreement with the hyperplasic shown by 
results obtained in DC skin (Figure 23). However, if DC patients are characterized by a 
low proliferation rate due to the lack of telomerase, these results are surprising and more 
studies will have to be made for a better explanation. 
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Keratin 14 
K14 is expressed in mitotically active basal layer cells in epidermis. The 
expression of k14 is down-regulated as cells differentiate. Then, it is used as a marker of 
level of differentiation in epidermal keratinocytes (Figure 23). 
 
Figure 23.Expression of k14 in control (left) and DC (right) epidermis. K14 is used as a marker 
of level of differentiation. Then, it is highly present in basal layer of epidermis. In control sample the result 
is the expected one, but in DC skin the k14 is expressed over the whole epidermis. This can be the 
explanation for the hyperplasic behavior of DC skin. 
 
Both samples present a similar expression of k14 in basal layer of the epidermis, 
which allow concluding that basal layer is composed by low differentiated cells. The 
interesting result obtained in the experiment is the expression of k14 in the suprabasal 
layer of the epidermis in DC skin. The result shows problems in the proliferation and 
differentiation of skin. The hyperplasic phenotype of DC skin can explain the abnormal 
expression of k14 out of the basal layer. 
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Vimentin 
Vimentin is a protein which forms the type III intermediate filaments. This type 
of filaments is expressed by fibroblast in dermal layer. Then, it is used as a marker for 
fibroblast concentration; it gives an overview of structure of dermis (Figure 24). 
 
Figure 24. Expression of vimentin in control (left) and DC (right) skin. Vimentin is used as a marker of fibroblast 
concentration in the dermal layer. In this case, both (control and DC skin) shows similar expression of vimentin in 
dermal layer. As a conclusion, DC has no effect over vimentin expression in fibroblast. Other markers could be use to 
better understand the behavior of dermal layer and dermal-epidermal junction. 
 
The images obtained in, both control and DC skin shows a similar expression of 
vimentin in dermal layer. Then, we can conclude that DC has no effect over vimentin in 
fibroblast.  
It would be necessary realize more immunohistochemical processes using 
fibroblast and ECM markers to determine the functionalization of dermal layer in 
diseased versus healthy skin. 
Some examples about possible markers for dermal layer could be: Desmin, 
another protein related with intermediate filaments; or Prolyl 4-hydroxilase, related with 
collagen synthesis. 
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4. In vivo development of skin-humanized mouse 
models for DC 
 
Two approaches were done for in vivo studies: Barrandon method and orthotopic 
graft. 
For both methods, bioengineered DC skin was used. 
 
The skin obtained by Barrandon method was analyzed using a blue-light 
microscope. (Figure 25): 
 
 
Figure 25. Image obtained with fluorescent microscope expressing GFP. The skin extracted from the mouse had 
been previously treated using Barrandon method to introduce bioengineered skin. Bioengineered skin needs to last for 
15 days to mature inside the mouse. The extracted skin is studied at fluorescent microscope. The GFP present in 
bioengineered skin keratinocytes is shown in fluorescent microscope. Then, we can conclude that human skin has 
matured in mouse model. 
 
The fluorescence produced by GFP in skin graft shows that bioengineered 
human skin is maturating inside the murine model. With this assumption, skin showing 
the fluorescence was taken and processed for histological studies. 
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After H&E staining, the following image was obtained: 
 
 
Figure 26. Bioengineered skin developed In vivo using Barrandon method. Skin obtained in 
figure 25, is paraffinize , treated with H&E staining and observed at microscope. The upper part of the 
image represents the human skin growth in mouse model. The zoom allows to see and differentiate among 
dermis, epidermis and stratum corneum. 
 
 
In the upper part of the image, it can be seen the regenerated human skin, where 
the dermis and different layers of keratinocytes, including the stratum corneum, can be 
differentiated. Although human skin is clearly visible different markers for human skin 
has to be made. 
 
The orthotopic graft was done, but due to it requires between two and three 
months to take and mature, the extraction of human skin has not been performed yet.  
But, it will be performed a posteriori. 
 
In the following image can be seen the integration of human skin in mouse: 
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Figure 27. Development of bioengineered skin In vivo using orthotopic method. The steps required for orthotopic 
method of murine skin transplantation are developed in figure 14. Instead of skin cannot be extracted until 2-3 
months after introduction of bioengineered skin, an evaluation of the integration of human skin in mouse model can 
be realized. The graft (black square) has been taken by the mouse and it is maturating. 
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Conclusion 
As a conclusion, the obtained results allow to explain briefly the 
functionalization of cells with Dyskeratosis Congenita disease. It has been generated an 
In vitro skin model able to recapitulate, at least in part, the pathological skin features of 
patients with DC.  
An In vivo skin model of DC has been also acquired. Those approaches allow 
creating feasible human skin models, which recapitulates better the structure and 
function of human skin as can be seen in Barrandon method model. Next result, with the 
orthotopic model, will give us more data about the physiopathology of this disease. 
It is important to remark that DC affect to telomeres which are related with cell 
aging. If a new experiment, over a longer period of time, is realized, some conclusions 
about the effect of aging in epidermal cells could be obtained. Moreover, the use of 
other markers can facilitate a better explanation of the diseased skin behavior. 
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Alternative applications and future lines 
Instead of the obtained results, more studies must be done to really understand 
the behavior of diseased skin over the normal one. 
 
The principal lines to improve actual techniques consist on the use of new 
models that mimic the human skin in the body. Nowadays animal models, specifically 
mice, are used for this kind of test. The idea is to use new animals that improve the 
similarity with respect to humans or the use of bioreactors controlling the necessary 
conditions to differentiate the skin, producing a good model of human skin. 
 
Another approach could be the use of “organ-on-a-chip”, in this case “skin-on-a-
chip”, that can be useful not only for the development of the skin but also for drug 
screening in unhealthy skin. 
 
The characterization of a disease can be done, in principle, for any tissue in the 
body (Instead some organs are much difficult to mimic). Then this process can facilitate 
the study of different diseases through the whole body. 
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Legal regulatory framework 
The final project is framed into a biomedical scientific research activity, which is 
recognized as a fundamental right of maximum protection in the article 20.1.b of the 
Spanish Constitution of 1978. 
 
Moreover, the specific legal regulation of biomedical investigation is present in 
law 14/2007 of July 3th. However, this law has been partially modified by the law 
14/2011 of science, technology and investigation. 
 
At international level, the law 14/2007 takes part of the Convention of the 
European Council for the protection of human rights and dignity of the human being 
with regard to the application of biology and medicine. In this law it is proclaimed the 
health, dignity and welfare of the human being who participates in the biomedical 
investigation, will prevail the interest of the society or the science. 
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Glossary of terms 
 
DC: Dyskeratosis congenital 
 
LC: Langerhans cells 
 
MSH: Melanocyte-stimulated hormone 
 
MC: Merkel cells 
 
DEJ: Dermal-epidermal junction 
 
TERT: Telomerase reverse transcriptase 
 
TERC: Telomerase RNA component 
 
DKC1: Dyskeratosis congénita 1, dyskeryn 
 
HIV-1: Human immunodefficiency virus 
 
LTR: Long terminal regions 
 
DMEM: Dulbbeco’s modified eagle medium 
 
GFP: Green fluorescent protein 
 
HBS: Hepes buffered saline 
 
DAPI: 4',6-diamidino-2-phenylindole 
 
K14: Keratin 14 
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